MARISSA DEMBEK: Open Payments
NPI 1376273334 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,308 in 224 payments from 17 companies in 2025. Trend: 2023 $3,524 · 2024 $5,787 · 2025 $5,308
Food & beverage: $5,206Education: $101
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 23 | $875 |
| Janssen Pharmaceuticals, Inc | 22 | $744 |
| Vanda Pharmaceuticals Inc. | 25 | $714 |
| ABBVIE INC. | 27 | $611 |
| Teva Pharmaceuticals USA, Inc. | 24 | $475 |
| Otsuka America Pharmaceutical, Inc. | 18 | $442 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $336 |
| Alkermes, Inc. | 11 | $248 |
| Lundbeck LLC | 14 | $208 |
| Axsome Therapeutics, Inc. | 8 | $190 |
Products named: INGREZZA, FANAPT, VRAYLAR, REXULTI, SPRAVATO, CAPLYTA, ARISTADA, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
